Pharmaceutical Market Trend Insight, Experts Talk GLP-1 Competition and More | AMCP Annual 2025

More than 4,000 managed care pharmacy professionals attended the 2025 Academy of Managed Care Pharmacy (AMCP) conference held last week in Houston. In the crowd were Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, and Doug Long, MBA, vice president of industry relations at IQVIA.

Long and Casberg gave presentations at AMCP, and although they spoke at different sessions, both touched on similar themes, including payer and drug trends, specifically when it comes to GLP-1s.

Casberg presented on April 2, speaking at the session titled Drug Pipeline: Traditional Pharmaceuticals (Brands and Generics).

“Overall, there's a lot of loss of exclusivity opportunities coming up for payers and PBMs in the next three to five years,” Casberg said in a video interview with Managed Healthcare Executive. “There are all kinds of new approvals coming, but there's also some opportunity for savings with big drugs losing exclusivity, both on the traditional side and the biologic side.”

He also touched on competition within the GLP-1 space.

“There's a whole pipeline of products coming,” he said. “In the immediate near future, 2026–2027, it's really going to be a broken record with Novo [Nordisk] and [Eli] Lily.”

Long also presented at the April 2 morning keynote session titled 2024-2025 Health Care and Pharmaceutical Marketplace Trends.

“The [GLP-1] market is continuing to grow,” Long said. “It's a 100 billion category. We're also starting to see some of these GLP-1s used for type one diabetes, and there are 170 in the pipeline now. The challenge is, is that they're expensive drugs, and third parties pay for them in some cases, but Medicaid doesn't cover them a lot, and Medicare doesn't cover them a lot. Maybe that will change in the future, but that's a big, big constraint right now.”

Long discussed biosimilar trends as well.

“There are about 128 biosimilars that are going to be expiring in the next 10 years, but only 12 are actively being pursued right now,” he said. “So, the challenge is, will biosimilars play the same role as generics did? Of saving healthcare costs to offset innovation? There's plenty of opportunity, but everybody seems to be going after oncology, immunology and [opthamology].”